Rolla, MO, September 30, 2025: Engineered Tissue Solutions (ETS), a leading innovator in synthetic wound care technologies, today announced the publication of results from a second randomized controlled trial (RCT) evaluating Mirragen®, the company’s borate-based bioactive glass fiber matrix, in the management of diabetic foot ulcers (DFUs). The peer-reviewed study appears in the International Wound Journal and reinforces Mirragen’s effectiveness in supporting wound closure with key statistically significant differences over the standard of care alone.

Key Results

• Primary Endpoint (Per Protocol): At 12 weeks, 73% of patients treated with Mirragen + Standard of Care (SOC) achieved complete wound closure, compared to 42% with SOC alone.
• Primary Endpoint (Modified Intent-to-Treat): In broader practice conditions, 48% of patients achieved complete wound closure with Mirragen + SOC at 12 weeks versus 24% with SOC alone.

This new, 148-patient study builds on ETS’s first 40-patient RCT on DFUs, which demonstrated similar wound closure outcomes. Together, the two trials confirm that the results are reproducible, reliable, and achieved under rigorous study designs —including the use of standardized offloading devices across all groups.

For the full press release, click here.